Eighteen milliliters of peripheral blood were collected for PBMCs preparation. They were isolated as described in Section 2.1.1. PBMCs were stained with FITC-labeled anti-human CD304, PE-Cy7-labeled anti-human CD123, APC-labeled anti-human CD86, and PE-labeled anti-human HLA-DR for pDCs and were stained with PE-Cy7-labeled anti-human CD11c, FITC-labeled anti-human Lin1, APC-labeled anti-human CD86, and PE-labeled anti-human HLA-DR (BD, Franklin Lakes, NJ, USA) for mDCs, following treatment with Horizon Fixable Viability Stain 780 (BD, Franklin Lakes, NJ, USA) and Human BD Fc Block (BD, Franklin Lakes, NJ, USA) treatment. The cells were then washed twice with Stain Buffer and fixed with Cytofix Buffer (BD, Franklin Lakes, NJ, USA) for FACS analysis. The data were processed and obtained using FlowJo ver. 7.6 (Tree Star, Ashland, OR, USA).
Li Y., Arai S., Kato K., Iwabuchi S., Iwabuchi N., Muto N., Motobayashi H., Ebihara S., Tanaka M, & Hashimoto S. (2023). The Potential Immunomodulatory Effect of Bifidobacterium longum subsp. longum BB536 on Healthy Adults through Plasmacytoid Dendritic Cell Activation in the Peripheral Blood. Nutrients, 16(1), 42.
+ Open protocol